Mapping the Research of Ferroptosis in Parkinson’s Disease from 2013 to 2023: A Scientometric Review

References

• He T, Lin X, Su A, et al. Mitochondrial dysfunction-targeting therapeutics of natural products in Parkinson’s disease. Front Pharmacol. 2023;14:1117337.
   PubMed Web of Science ®Google Scholar
• Collaborators GBDPs D. Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939–953.
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis. 2018;8(s1):S3–S8.
   PubMedGoogle Scholar
• Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 2021;20(5):385–397.
   PubMed Web of Science ®Google Scholar
• Chen YC, Liaw YC, Nfor ON, et al. Epigenetic regulation of Parkinson’s disease risk variant GPNMB cg17274742 methylation by sex and exercise from Taiwan Biobank. Front Aging Neurosci. 2023;15:1235840.
   PubMed Web of Science ®Google Scholar
• Geng Y, Long X, Zhang Y, et al. FTO-targeted siRNA delivery by MSC-derived exosomes synergistically alleviates dopaminergic neuronal death in Parkinson’s disease via m6A-dependent regulation of ATM mRNA. J Transl Med. 2023;21(1):652.
   PubMed Web of Science ®Google Scholar
• Moujalled D, Strasser A, Liddell JR. Molecular mechanisms of cell death in neurological diseases. Cell Death Differ. 2021;28(7):2029–2044.
   PubMed Web of Science ®Google Scholar
• Dexter DT, Wells FR, Agid F, et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet. 1987;2(8569):1219–1220.
   PubMed Web of Science ®Google Scholar
• Dexter D, Carter C, Agid F, et al. Lipid peroxidation as cause of nigral cell death in Parkinson’s disease. Lancet. 1986;2(8507):639–640.
   PubMed Web of Science ®Google Scholar
• Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol. 1994;36(3):348–355.
   PubMed Web of Science ®Google Scholar
• Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299(5604):256–259.
   PubMed Web of Science ®Google Scholar
• Bersuker K, Hendricks JM, Li Z, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575(7784):688–692.
   PubMed Web of Science ®Google Scholar
• Mahoney-Sanchez L, Bouchaoui H, Ayton S, Devos D, Duce JA, Devedjian JC. Ferroptosis and its potential role in the physiopathology of Parkinson’s Disease. Prog Neurobiol. 2021;196.
   Web of Science ®Google Scholar
• Wang ZL, Yuan L, Li W, Li JY. Ferroptosis in Parkinson’s disease: glia-neuron crosstalk. Trends Mol Med. 2022;28(4):258–269.
   PubMed Web of Science ®Google Scholar
• Chen C, Song M. Visualizing a field of research: a methodology of systematic scientometric reviews. PLoS One. 2019;14(10):e0223994.
   PubMed Web of Science ®Google Scholar
• Si W, Huang Z, Li X, et al. Super-enhancer-driven Sorting Nexin 5 expression promotes dopaminergic neuronal ferroptosis in Parkinson’s disease models. Biochem Biophys Res Commun. 2021;567:35–41.
   PubMed Web of Science ®Google Scholar
• Huang Z, Han J, Wu P, et al. Sorting Nexin 5 Plays an Important Role in Promoting Ferroptosis in Parkinson’s Disease. Oxid Med Cell Longev. 2022;2022:5463134.
   PubMed Web of Science ®Google Scholar
• Bouchaoui H, Mahoney-Sanchez L, Garçon G, et al. ACSL4 and the lipoxygenases 15/15B are pivotal for ferroptosis induced by iron and PUFA dyshomeostasis in dopaminergic neurons. Free Radic Biol Med. 2023;195(8):145–157.
   PubMedGoogle Scholar
• Mahoney-Sanchez L, Bouchaoui H, Boussaad I, et al. Alpha synuclein determines ferroptosis sensitivity in dopaminergic neurons via modulation of ether-phospholipid membrane composition. Cell Rep. 2022;40(8):111231.
   PubMed Web of Science ®Google Scholar
• Jiang L, Chen XB, Wu Q, et al. The C terminus of DJ-1 determines its homodimerization, MGO detoxification activity and suppression of ferroptosis. Acta Pharmacol Sin. 2021;42(7):1150–1159.
   PubMed Web of Science ®Google Scholar
• Zeng X, An H, Yu F, et al. Benefits of Iron Chelators in the Treatment of Parkinson’s Disease. Neurochem Res. 2021;46(5):1239–1251.
   PubMed Web of Science ®Google Scholar
• Lin F, Chen Y, Mo W, et al. A bibliometric analysis of autophagy in lung diseases from 2012 to 2021. Front Immunol. 2022;13:1092575.
   PubMedGoogle Scholar
• Do Van B, Gouel F, Jonneaux A, et al. Ferroptosis, a newly characterized form of cell death in Parkinson’s disease that is regulated by PKC. Neurobiol Dis. 2016;94:169–178.
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an Iron-Dependent Form of Nonapoptotic Cell Death. Cell. 2012;149(5):1060–1072.
   PubMed Web of Science ®Google Scholar
• Angeli JPF, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16(12):567.
   Web of Science ®Google Scholar
• Devos D, Moreau C, Devedjian JC, et al. Targeting chelatable iron as a therapeutic modality in Parkinson’s disease. Antioxid Redox Signal. 2014;21(2):195–210.
   PubMed Web of Science ®Google Scholar
• Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A. 2016;113(34):E4966–75.
   PubMed Web of Science ®Google Scholar
• Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of Ferroptotic Cancer Cell Death by GPX4. Cell. 2014;156(1–2).
   PubMed Web of Science ®Google Scholar
• Skouta R, Dixon SJ, Wang JL, et al. Ferrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models. J Am Chem Soc. 2014;136(12):4551–4556.
   PubMed Web of Science ®Google Scholar
• Gao MH, Monian P, Quadri N, Ramasamy R, Jiang XJ. Glutaminolysis and Transferrin Regulate Ferroptosis. Molecular Cell. 2015;59(2):298–308.
   PubMed Web of Science ®Google Scholar
• Ayton S, Lei P, Hare DJ, et al. Parkinson’s Disease Iron Deposition Caused by Nitric Oxide-Induced Loss of β-Amyloid Precursor Protein. J Neurosci. 2015;35(8):3591–3597.
   PubMed Web of Science ®Google Scholar
• Jiang L, Kon N, Li TY, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57–62.
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Winter GE, Musavi LS, et al. Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. ACS Chem Biol. 2015;10(7):1604–1609.
   PubMed Web of Science ®Google Scholar
• Hambright WS, Fonseca RS, Chen LJ, Na R, Ran QT. Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol. 2017;12:8–17. doi:10.1016/j.redox.2017.01.021
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nature Chem Biol. 2014;10(1):9–17. doi:10.1038/nchembio.1416
   PubMed Web of Science ®Google Scholar
• Xie Y, Hou W, Song X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23(3):369–379.
   PubMed Web of Science ®Google Scholar
• Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63(1):173–184.
   PubMed Web of Science ®Google Scholar
• Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017;171(2):273–285.
   PubMed Web of Science ®Google Scholar
• Guiney SJ, Adlard PA, Bush AI, Finkelstein DI, Ayton S. Ferroptosis and cell death mechanisms in Parkinson’s disease. Neurochem Int. 2017;104:34–48.
   PubMed Web of Science ®Google Scholar
• Angelova PR, Choi ML, Berezhnov AV, et al. Alpha synuclein aggregation drives ferroptosis: an interplay of iron, calcium and lipid peroxidation. Cell Death Differ. 2020;27(10):2781–2796.
   PubMed Web of Science ®Google Scholar
• Masaldan S, Bush AI, Devos D, Rolland AS, Moreau C. Striking while the iron is hot: iron metabolism and ferroptosis in neurodegeneration. Free Radic Biol Med. 2019;133:221–233.
   PubMed Web of Science ®Google Scholar
• Zhang P, Chen L, Zhao Q, et al. Ferroptosis was more initial in cell death caused by iron overload and its underlying mechanism in Parkinson’s disease. Free Radic Biol Med. 2020;152:227–234.
   PubMed Web of Science ®Google Scholar
• Weiland A, Wang YM, Wu WH, et al. Ferroptosis and Its Role in Diverse Brain Diseases. Mol Neurobiol. 2019;56(7):4880–4893.
   PubMed Web of Science ®Google Scholar
• Tian Y, Lu J, Hao XQ, et al. FTH1 Inhibits Ferroptosis Through Ferritinophagy in the 6-OHDA Model of Parkinson’s Disease. Neurotherapeutics. 2020;17(4):1796–1812.
   PubMed Web of Science ®Google Scholar
• Abdalkader M, Lampinen R, Kanninen KM, Malm TM, Liddell JR. Targeting Nrf2 to Suppress Ferroptosis and Mitochondrial Dysfunction in Neurodegeneration. Front Neurosci. 2018;12:466.
   PubMed Web of Science ®Google Scholar
• Sun YR, He LB, Wang TY, et al. Activation of p62-Keap1-Nrf2 Pathway Protects 6-Hydroxydopamine-Induced Ferroptosis in Dopaminergic Cells. Mol Neurobiol. 2020;57(11):4628–4641.3.
   PubMed Web of Science ®Google Scholar
• Southon A, Szostak K, Acevedo KM, et al. CuII (atsm) inhibits ferroptosis: implications for treatment of neurodegenerative disease. Br J Pharmacol. 2020;177(3):656–667.
   PubMed Web of Science ®Google Scholar
• Ito K, Eguchi Y, Imagawa Y, Akai S, Mochizuki H, Tsujimoto Y. MPP+ induces necrostatin-1- and ferrostatin-1-sensitive necrotic death of neuronal SH-SY5Y cells. Cell Death Discov. 2017;3:17013.
   PubMed Web of Science ®Google Scholar
• Liddell JR, White AR. Nexus between mitochondrial function, iron, copper and glutathione in Parkinson’s disease. Neurochem Int. 2018;117:126–138.
   PubMed Web of Science ®Google Scholar
• Devos D, Cabantchik ZI, Moreau C, et al. Conservative iron chelation for neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis. J Neural Transm. 2020;127(2):189–203.
   PubMed Web of Science ®Google Scholar
• Chen LJ, Hambright WS, Na R, Ran QT. Ablation of the Ferroptosis Inhibitor Glutathione Peroxidase 4 in Neurons Results in Rapid Motor Neuron Degeneration and Paralysis. J Biol Chem. 2015;290(47):28097–28106.
   PubMed Web of Science ®Google Scholar
• Ayton S, Lei P. Nigral Iron Elevation Is an Invariable Feature of Parkinson’s Disease and Is a Sufficient Cause of Neurodegeneration. Biomed Res Int. 2014;2014:581256.
   PubMed Web of Science ®Google Scholar
• Li Q, Han XN, Lan X, et al. Inhibition of neuronal ferroptosis protects hemorrhagic brain. Jci Insight. 2017;2(7):e90777.
   PubMed Web of Science ®Google Scholar
• Hare DJ, Double KL. Iron and dopamine: a toxic couple. Brain. 2016;139(4):1026–1035.
   PubMedGoogle Scholar
• Shimada K, Skouta R, Kaplan A, et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat Chem Biol. 2016;12(7):497–503.
   PubMed Web of Science ®Google Scholar
• Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91–98.
   PubMed Web of Science ®Google Scholar
• Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81–90.
   PubMed Web of Science ®Google Scholar
• Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575(7784):693–698.
   PubMed Web of Science ®Google Scholar
• Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15(3):234–245.
   PubMedGoogle Scholar
• Ward R, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13(10):1045–1060.
   PubMed Web of Science ®Google Scholar
• Yang WS, Stockwell BR. Ferrootosis: death by Lipid Peroxidation. Trends Cell Biol. 2016;26(3):165–176.
   PubMed Web of Science ®Google Scholar
• Martin-Bastida A, Ward RJ, Newbould R, et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease. Sci Rep. 2017;7(1):1398.
   PubMed Web of Science ®Google Scholar
• Yagoda N, Von Rechenberg M, Zaganjor E, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 2007;447(7146):864–868.
   PubMed Web of Science ®Google Scholar
• Yuan H, Li XM, Zhang XY, Kang R, Tang DL. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem Biophys Res Commun. 2016;478(3):1338–1343.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Cao Y, Cao W, Jia Y, Lu N. The Application of Ferroptosis in Diseases. Pharmacol Res. 2020;159:104919.
   PubMed Web of Science ®Google Scholar
• Angelova PR, Esteras N, Abramov AY. Mitochondria and lipid peroxidation in the mechanism of neurodegeneration: finding ways for prevention. Med Res Rev. 2021;41(2):770–784.
   PubMed Web of Science ®Google Scholar
• Thapa K, Khan H, Kanojia N, Singh TG, Kaur A, Kaur G. Therapeutic Insights on Ferroptosis in Parkinson’s disease. Eur J Pharmacol. 2022;930:175133.
   PubMed Web of Science ®Google Scholar
• Han X, Zhang J, Chen S, Yu W, Zhou Y, Gu X. Mapping the current trends and hotspots of vascular cognitive impairment from 2000-2021: a bibliometric analysis. CNS Neurosci Ther. 2023;29(3):771–782.
   PubMed Web of Science ®Google Scholar
• Li Y, Zheng JJ, Wu X, Gao W, Liu CJ. Postural control of Parkinson’s disease: a visualized analysis based on Citespace knowledge graph. Front Aging Neurosci. 2023;15:1136177.
   PubMed Web of Science ®Google Scholar
• Zhong D, Luo S, Zheng L, Zhang Y, Jin R. Epilepsy Occurrence and Circadian Rhythm: a Bibliometrics Study and Visualization Analysis via CiteSpace. Front Neurol. 2020;11:984.
   PubMed Web of Science ®Google Scholar
• Villalon-Garcia I, Povea-Cabello S, Alvarez-Cordoba M, et al. Vicious cycle of lipid peroxidation and iron accumulation in neurodegeneration. Neural Regen Res. 2023;18(6):1196–1202.
   PubMed Web of Science ®Google Scholar
• Villalon-Garcia I, Alvarez-Cordoba M, Povea-Cabello S, et al. Vitamin E prevents lipid peroxidation and iron accumulation in PLA2G6-Associated Neurodegeneration. Neurobiol Dis. 2022;165:105649.
   PubMed Web of Science ®Google Scholar
• Hohn A, Jung T, Grimm S, Grune T. Lipofuscin-bound iron is a major intracellular source of oxidants: role in senescent cells. Free Radic Biol Med. 2010;48(8):1100–1108.
   PubMed Web of Science ®Google Scholar
• Zeidan RS, Han SM, Leeuwenburgh C, Xiao R. Iron homeostasis and organismal aging. Ageing Res Rev. 2021;72:101510.
   PubMed Web of Science ®Google Scholar
• Brunk UT, Terman A. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med. 2002;33(5):611–619.
   PubMed Web of Science ®Google Scholar
• Moore MN, Sforzini S, Viarengo A, et al. Antagonistic cytoprotective effects of C(60) fullerene nanoparticles in simultaneous exposure to benzo[a]pyrene in a molluscan animal model. Sci Total Environ. 2021;755(Pt 1):142355.
   PubMedGoogle Scholar
• Tian Y, Tian Y, Yuan Z, et al. Iron Metabolism in Aging and Age-Related Diseases. Int J Mol Sci. 2022;23(7):3612.
   PubMed Web of Science ®Google Scholar
• Tian R, Abarientos A, Hong J, et al. Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis. Nat Neurosci. 2021;24(7):1020–1034.
   PubMed Web of Science ®Google Scholar
• Shi L, Huang C, Luo Q, et al. The Association of Iron and the Pathologies of Parkinson’s Diseases in MPTP/MPP(+)-Induced Neuronal Degeneration in Non-human Primates and in Cell Culture. Front Aging Neurosci. 2019;11:215.
   PubMed Web of Science ®Google Scholar
• Belaidi AA, Bush AI. Iron neurochemistry in Alzheimer’s disease and Parkinson’s disease: targets for therapeutics. J Neurochem. 2016;139(Suppl 1):179–197.
   PubMedGoogle Scholar
• Thomas GEC, Leyland LA, Schrag AE, Lees AJ, Acosta-Cabronero J, Weil RS. Brain iron deposition is linked with cognitive severity in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2020;91(4):418–425.
   PubMed Web of Science ®Google Scholar
• Pesch B, Casjens S, Woitalla D, et al. Impairment of Motor Function Correlates with Neurometabolite and Brain Iron Alterations in Parkinson’s Disease. Cells. 2019;8(2):96.
   PubMed Web of Science ®Google Scholar
• Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem. 1989;52(6):1830–1836.
   PubMed Web of Science ®Google Scholar
• Cho SJ, Bae YJ, Kim JM, et al. Iron-sensitive magnetic resonance imaging in Parkinson’s disease: a systematic review and meta-analysis. J Neurol. 2021;268(12):4721–4736.
   PubMed Web of Science ®Google Scholar
• Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson’s disease: a LAMMA study. Brain Res. 1992;593(2):343–346.
   PubMed Web of Science ®Google Scholar
• Wang Z, Luo XG, Gao C. Utility of susceptibility-weighted imaging in Parkinson’s disease and atypical Parkinsonian disorders. Transl Neurodegener. 2016;5:17.
   PubMed Web of Science ®Google Scholar
• Wang JY, Zhuang QQ, Zhu LB, et al. Meta-analysis of brain iron levels of Parkinson’s disease patients determined by postmortem and MRI measurements. Sci Rep. 2016;6:36669.
   PubMed Web of Science ®Google Scholar
• Ji S, Zhang S, Mao Z, et al. Quantitative assessment of iron deposition in Parkinson’s disease using enhanced T2 star-weighted angiography. Neurol India. 2016;64(3):428–435.
   PubMed Web of Science ®Google Scholar
• Biondetti E, Santin MD, Valabrègue R, et al. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s disease. Brain. 2021;144(10):3114–3125.
   PubMedGoogle Scholar
• Song N, Wang J, Jiang H, Xie J. Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson’s disease. Free Radic Biol Med. 2010;48(2):332–341.
   PubMed Web of Science ®Google Scholar
• Jiang H, Song N, Xu H, Zhang S, Wang J, Xie J. Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent. Cell Res. 2010;20(3):345–356.
   PubMed Web of Science ®Google Scholar
• Zhao X, Shao Z, Zhang Y, Liu F, Liu Z, Liu Z. Ceruloplasmin in Parkinson’s disease and the nonmotor symptoms. Brain Behav. 2018;8(6):e00995.
   PubMed Web of Science ®Google Scholar
• Barbariga M, Curnis F, Andolfo A, et al. Ceruloplasmin functional changes in Parkinson’s disease-cerebrospinal fluid. Mol Neurodegener. 2015;10:59.
   PubMed Web of Science ®Google Scholar
• Lei P, Ayton S, Finkelstein DI, et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med. 2012;18(2):291–295.
   PubMed Web of Science ®Google Scholar
• Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron. 2003;37(6):899–909.
   PubMed Web of Science ®Google Scholar
• Blackinton J, Kumaran R, van der Brug MP, et al. Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinson disease. Neurosci Lett. 2009;452(1):8–11.
   PubMed Web of Science ®Google Scholar
• Bellinger FP, Bellinger MT, Seale LA, et al. Glutathione Peroxidase 4 is associated with Neuromelanin in Substantia Nigra and Dystrophic Axons in Putamen of Parkinson’s brain. Mol Neurodegener. 2011;6(1):8.
   PubMedGoogle Scholar
• Vallerga CL, Zhang F, Fowdar J, et al. Analysis of DNA methylation associates the cystine-glutamate antiporter SLC7A11 with risk of Parkinson’s disease. Nat Commun. 2020;11(1):1238.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ma X, Fujioka H, Liu J, Chen S, Zhu X. DJ-1 regulates the integrity and function of ER-mitochondria association through interaction with IP3R3-Grp75-VDAC1. Proc Natl Acad Sci U S A. 2019;116(50):25322–25328.
   PubMed Web of Science ®Google Scholar
• Cao J, Chen X, Jiang L, et al. DJ-1 suppresses ferroptosis through preserving the activity of S-adenosyl homocysteine hydrolase. Nat Commun. 2020;11(1):1251.
   PubMed Web of Science ®Google Scholar
• Guo Q, Wang B, Wang X, Smith WW, Zhu Y, Liu Z. Activation of Nrf2 in Astrocytes Suppressed PD-Like Phenotypes via Antioxidant and Autophagy Pathways in Rat and Drosophila Models. Cells. 2021;10(8):1850.
   PubMed Web of Science ®Google Scholar
• Xiao H, Lv F, Xu W, Zhang L, Jing P, Cao X. Deprenyl prevents MPP(+)-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk. Toxicology. 2011;290(2–3):286–294.
   PubMed Web of Science ®Google Scholar
• Anandhan A, Chen W, Nguyen N, Madhavan L, Dodson M, Zhang DD. α-Syn overexpression, NRF2 suppression, and enhanced ferroptosis create a vicious cycle of neuronal loss in Parkinson’s disease. Free Radic Biol Med. 2022;192:130–140.
   PubMed Web of Science ®Google Scholar
• Zeitler L, Fiore A, Meyer C, et al. Anti-ferroptotic mechanism of IL4i1-mediated amino acid metabolism. Elife. 2021;10:e64806.
   PubMed Web of Science ®Google Scholar
• Costa I, Barbosa DJ, Benfeito S, et al. Molecular mechanisms of ferroptosis and their involvement in brain diseases. Pharmacol Ther. 2023;108373.
   PubMed Web of Science ®Google Scholar
• Cleren C, Yang L, Lorenzo B, et al. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem. 2008;104(6):1613–1621.
   PubMed Web of Science ®Google Scholar
• Mischley LK, Allen J, Bradley R. Coenzyme Q10 deficiency in patients with Parkinson’s disease. J Neurol Sci. 2012;318(1–2):567.
   Web of Science ®Google Scholar
• Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem. 1989;52(2):381–389.
   PubMed Web of Science ®Google Scholar
• Sharon R, Bar-Joseph I, Mirick GE, Serhan CN, Selkoe DJ. Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem. 2003;278(50):49874–49881.
   PubMed Web of Science ®Google Scholar
• Fedorova TN, Logvinenko AA, Poleshchuk VV. Lipid Peroxidation Products in the Blood Plasma of Patients with Parkinson’s Disease as Possible Biomarkers of Different Stages of the Disease. Neurochemical J. 2019;13(4):391–395.
   Web of Science ®Google Scholar
• Tang F, Zhou LY, Li P, et al. Inhibition of ACSL4 Alleviates Parkinsonism Phenotypes by Reduction of Lipid Reactive Oxygen Species. Neurotherapeutics. 2023;20(4):1154–1166.
   PubMed Web of Science ®Google Scholar
• Yue M, Wei J, Chen W, Hong D, Chen T, Fang X. Neurotrophic Role of the Next-Generation Probiotic Strain L. lactis MG1363-pMG36e-GLP-1 on Parkinson’s Disease via Inhibiting Ferroptosis. Nutrients. 2022;14(22):4886.
   PubMed Web of Science ®Google Scholar
• Yu X, Yang Y, Zhang B, et al. Ketone Body β-Hydroxybutyric Acid Ameliorates Dopaminergic Neuron Injury Through Modulating Zinc Finger Protein 36/Acyl-CoA Synthetase Long-Chain Family Member Four Signaling Axis-Mediated Ferroptosis. Neuroscience. 2023;509:157–172.
   PubMed Web of Science ®Google Scholar
• Chen D, Chu B, Yang X, et al. iPLA2β-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4. Nat Commun. 2021;12(1):3644.
   PubMed Web of Science ®Google Scholar
• Beharier O, Tyurin VA, Goff JP, et al. PLA2G6 guards placental trophoblasts against ferroptotic injury. Proc Natl Acad Sci U S A. 2020;117(44):27319–27328.
   PubMed Web of Science ®Google Scholar
• Sun WY, Tyurin VA, Mikulska-Ruminska K, et al. Phospholipase iPLA2β averts ferroptosis by eliminating a redox lipid death signal. Nat Chem Biol. 2021;17(4):465–476. doi:10.1038/s41589-020-00734-x
   PubMed Web of Science ®Google Scholar
• Guo JJ, Yue F, Song DY, et al. Intranasal administration of α-synuclein preformed fibrils triggers microglial iron deposition in the substantia nigra of Macaca fascicularis. Cell Death Dis. 2021;12(1):81.
   PubMed Web of Science ®Google Scholar
• Minakaki G, Krainc D, Burbulla LF. The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinson’s Disease. Front Cell Dev Biol. 2020;8:580634.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Chen X, Huang S, et al. Iron promotes α-synuclein aggregation and transmission by inhibiting TFEB-mediated autophagosome-lysosome fusion. J Neurochem. 2018;145(1):34–50.
   PubMed Web of Science ®Google Scholar
• el-Agnaf OM, Irvine GB. Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem Soc Trans. 2002;30(4):559–565.
   PubMedGoogle Scholar
• Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson’s disease and heavy metal exposure. J Biol Chem. 2001;276(47):44284–44296.
   PubMed Web of Science ®Google Scholar
• Peng Y, Wang C, Xu HH, Liu YN, Zhou F. Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes. J Inorg Biochem. 2010;104(4):365–370.
   PubMed Web of Science ®Google Scholar
• Golts N, Snyder H, Frasier M, Theisler C, Choi P, Wolozin B. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J Biol Chem. 2002;277(18):16116–16123.
   PubMed Web of Science ®Google Scholar
• Friedlich AL, Tanzi RE, Rogers JT. The 5’-untranslated region of Parkinson’s disease alpha-synuclein messenger RNA contains a predicted iron responsive element. Mol Psychiatry. 2007;12(3):222–223.
   PubMed Web of Science ®Google Scholar
• Febbraro F, Giorgi M, Caldarola S, Loreni F, Romero-Ramos M. α-Synuclein expression is modulated at the translational level by iron. Neuroreport. 2012;23(9):576–580.
   PubMed Web of Science ®Google Scholar
• Cahill CM, Lahiri DK, Huang X, Rogers JT. Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochim Biophys Acta. 2009;1790(7):615–628.
   PubMed Web of Science ®Google Scholar
• Davies P, Moualla D, Brown DR. Alpha-synuclein is a cellular ferrireductase. PLoS One. 2011;6(1):e15814.
   PubMed Web of Science ®Google Scholar
• Alam P, Bousset L, Melki R, Otzen DE. α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J Neurochemistry. 2019;150(5):522–534.
   PubMed Web of Science ®Google Scholar
• Binolfi A, Rasia RM, Bertoncini CW, et al. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J Am Chem Soc. 2006;128(30):9893–9901. doi:10.1021/ja0618649
   PubMed Web of Science ®Google Scholar
• Longhena F, Faustini G, Bellucci A. Study of alpha-synuclein fibrillation: state of the art and expectations. Neural Regen Res. 2020;15(1):59–60.
   PubMed Web of Science ®Google Scholar
• Lin KJ, Chen SD, Lin KL, et al. Iron Brain Menace: the Involvement of Ferroptosis in Parkinson Disease. Cells. 2022;11(23):3829.
   PubMed Web of Science ®Google Scholar
• Baksi S, Tripathi AK, Singh N. Alpha-synuclein modulates retinal iron homeostasis by facilitating the uptake of transferrin-bound iron: implications for visual manifestations of Parkinson’s disease. Free Radic Biol Med. 2016;97:292–306.
   PubMed Web of Science ®Google Scholar
• Bi M, Du X, Jiao Q, Liu Z, Jiang H. α-Synuclein Regulates Iron Homeostasis via Preventing Parkin-Mediated DMT1 Ubiquitylation in Parkinson’s Disease Models. ACS Chem Neurosci. 2020;11(11):1682–1691.
   PubMed Web of Science ®Google Scholar
• Zhu ZJ, Wu KC, Yung WH, Qian ZM, Ke Y. Differential interaction between iron and mutant alpha-synuclein causes distinctive Parkinsonian phenotypes in Drosophila. Biochim Biophys Acta. 2016;1862(4):518–525.
   PubMed Web of Science ®Google Scholar
• Jia F, Song N, Wang W, Du X, Chi Y, Jiang H. High Dietary Iron Supplement Induces the Nigrostriatal Dopaminergic Neurons Lesion in Transgenic Mice Expressing Mutant A53T Human Alpha-Synuclein. Front Aging Neurosci. 2018;10:97.
   PubMed Web of Science ®Google Scholar
• Febbraro F, Andersen KJ, Sanchez-Guajardo V, Tentillier N, Romero-Ramos M. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson’s model. Exp Neurol. 2013;247:45–58.
   PubMed Web of Science ®Google Scholar
• Carboni E, Tatenhorst L, Tönges L, et al. Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein Aggregation. Neuromolecular Med. 2017;19(2–3).
   PubMed Web of Science ®Google Scholar
• Golovko MY, Rosenberger TA, Faergeman NJ, et al. Acyl-CoA synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolism. Biochemistry. 2006;45(22):6956–6966.
   PubMed Web of Science ®Google Scholar
• Ouberai MM, Wang J, Swann MJ, et al. α-Synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling. J Biol Chem. 2013;288(29):20883–20895.
   PubMed Web of Science ®Google Scholar
• Shahmoradian SH, Lewis AJ, Genoud C, et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat Neurosci. 2019;22(7):1099–1109.
   PubMed Web of Science ®Google Scholar
• Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology. 1985;35(7):949–956.
   PubMed Web of Science ®Google Scholar
• Lin KJ, Wang TJ, Chen SD, et al. Two Birds One Stone: the Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease-Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors. Antioxidants (Basel). 2021;10(12):1935.
   PubMedGoogle Scholar
• Nguyen M, Wong YC, Ysselstein D, Severino A, Krainc D. Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson’s Disease. Trends Neurosci. 2019;42(2):140–149.
   PubMed Web of Science ®Google Scholar
• Lesage S, Drouet V, Majounie E, et al. Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. Am J Hum Genet. 2016;98(3):500–513.
   PubMed Web of Science ®Google Scholar
• Gregory A, Westaway SK, Holm IE, et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology. 2008;71(18):1402–1409.
   PubMed Web of Science ®Google Scholar
• Kinghorn KJ, Castillo-Quan JI, Bartolome F, et al. Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction. Brain. 2015;138(7):1801–1816.
   PubMedGoogle Scholar
• Smolders S, Van Broeckhoven C. Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson’s disease pathogenesis. Acta Neuropathol Commun. 2020;8(1):63.
   PubMed Web of Science ®Google Scholar
• Billingsley KJ, Barbosa IA, Bandrés-Ciga S, et al. Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset. NPJ Parkinsons Dis. 2019;5:8.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu N, Lu B. Mechanisms and roles of mitophagy in neurodegenerative diseases. CNS Neurosci Ther. 2019;25(7):859–875. doi:10.1111/cns.13140
   PubMed Web of Science ®Google Scholar
• Daher B, Vučetić M, Pouysségur J. Cysteine Depletion, a Key Action to Challenge Cancer Cells to Ferroptotic Cell Death. Front Oncol. 2020;10:723.
   PubMed Web of Science ®Google Scholar
• Chen X, Kang R, Kroemer G, Tang D. Organelle-specific regulation of ferroptosis. Cell Death Differ. 2021;28(10):2843–2856.
   PubMed Web of Science ®Google Scholar
• Mailloux RJ. An Update on Mitochondrial Reactive Oxygen Species Production. Antioxidants (Basel). 2020;9(6):472.
   PubMedGoogle Scholar
• Andréasson C, Ott M, Büttner S. Mitochondria orchestrate proteostatic and metabolic stress responses. EMBO Rep. 2019;20(10):e47865.
   PubMed Web of Science ®Google Scholar
• Gan B. Mitochondrial regulation of ferroptosis. J Cell Biol. 2021;220(9):e202105043.
   PubMed Web of Science ®Google Scholar
• Wang YQ, Chang SY, Wu Q, et al. The Protective Role of Mitochondrial Ferritin on Erastin-Induced Ferroptosis. Front Aging Neurosci. 2016;8:308.
   PubMed Web of Science ®Google Scholar
• Tsubaki H, Yanagisawa D, Kageyama Y, Hafiz Abu Baker Z, Mukaisho KI, Tooyama I. Immunohistochemical Analysis of Mitochondrial Ferritin in the Midbrain of Patients with Parkinson’s Disease. Acta Histochem Cytochem. 2023;56(2):21–27.
   PubMed Web of Science ®Google Scholar
• Chan S, Lian Q, Chen MP, et al. Deferiprone inhibits iron overload-induced tissue factor bearing endothelial microparticle generation by inhibition oxidative stress induced mitochondrial injury, and apoptosis. Toxicol Appl Pharmacol. 2018;338:148–158.
   PubMed Web of Science ®Google Scholar
• Alvarez SW, Sviderskiy VO, Terzi EM, et al. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis. Nature. 2017;551(7682):639–643.
   PubMed Web of Science ®Google Scholar
• Mao C, Liu X, Zhang Y, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021;593(7860):586–590.
   PubMed Web of Science ®Google Scholar
• Gao M, Yi J, Zhu J, et al. Role of Mitochondria in Ferroptosis. Mol Cell. 2019;73(2):354–363.e3.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Ding H, Xu M, Gao J. Protective effects of asiatic acid on rotenone- or H2O2-induced injury in SH-SY5Y cells. Neurochem Res. 2009;34(4):746–754.
   PubMed Web of Science ®Google Scholar
• Chaudhuri AD, Choi DC, Kabaria S, Tran A, Junn E. MicroRNA-7 Regulates the Function of Mitochondrial Permeability Transition Pore by Targeting VDAC1 Expression. J Biol Chem. 2016;291(12):6483–6493.
   PubMed Web of Science ®Google Scholar
• Magalingam KB, Somanath SD, Ramdas P, Haleagrahara N, Radhakrishnan AK. 6-Hydroxydopamine Induces Neurodegeneration in Terminally Differentiated SH-SY5Y Neuroblastoma Cells via Enrichment of the Nucleosomal Degradation Pathway: a Global Proteomics Approach. J Mol Neurosci. 2022;72(5):1026–1046.
   PubMed Web of Science ®Google Scholar
• Nagakannan P, Islam MI, Karimi-Abdolrezaee S, Eftekharpour E. Inhibition of VDAC1 Protects Against Glutamate-Induced Oxytosis and Mitochondrial Fragmentation in Hippocampal HT22 Cells. Cell Mol Neurobiol. 2019;39(1):73–85.
   PubMed Web of Science ®Google Scholar
• Wen S, Aki T, Unuma K, Uemura K. Chemically Induced Models of Parkinson’s Disease: history and Perspectives for the Involvement of Ferroptosis. Front Cell Neurosci. 2020;14:581191.
   PubMed Web of Science ®Google Scholar
• Mustapha M, Mat Taib CN. MPTP-induced mouse model of Parkinson’s disease: a promising direction of therapeutic strategies. Bosn J Basic Med Sci. 2021;21(4):422–433.
   PubMed Web of Science ®Google Scholar
• Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect. 2011;119(6):866–872.
   PubMed Web of Science ®Google Scholar
• Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem. 2002;277(3):1641–1644.
   PubMed Web of Science ®Google Scholar
• Bus JS, Aust SD, Gibson JE. Paraquat toxicity: proposed mechanism of action involving lipid peroxidation. Environ Health Perspect. 1976;139–146.
   PubMed Web of Science ®Google Scholar
• Fernagut PO, Hutson CB, Fleming SM, et al. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse. 2007;61(12):991–1001.
   PubMed Web of Science ®Google Scholar
• Yang WS, Tiffany-Castiglioni E. The bipyridyl herbicide paraquat produces oxidative stress-mediated toxicity in human neuroblastoma SH-SY5Y cells: relevance to the dopaminergic pathogenesis. J Toxicol Environ Heal A. 2005;68(22):1939–1961.
   PubMed Web of Science ®Google Scholar
• Niso-Santano M, González-Polo RA, Bravo-San Pedro JM, et al. Activation of apoptosis signal-regulating kinase 1 is a key factor in paraquat-induced cell death: modulation by the Nrf2/Trx axis. Free Radic Biol Med. 2010;48(10):1370–1381.
   PubMed Web of Science ®Google Scholar
• Cristóvao AC, Choi DH, Baltazar G, Beal MF, Kim YS. The Role of NADPH Oxidase 1-Derived Reactive Oxygen Species in Paraquat-Mediated Dopaminergic Cell Death. Antioxid Redox Sign. 2009;11(9):2105–2118.
   PubMed Web of Science ®Google Scholar
• Castello PR, Drechsel DA, Patel M. Mitochondria are a major source of paraquat-induced reactive oxygen species production in the brain. J Biol Chem. 2007;282(19):14186–14193.
   PubMed Web of Science ®Google Scholar
• Hou LY, Huang RX, Sun FQ, Zhang L, Wang QS. NADPH oxidase regulates paraquat and maneb-induced dopaminergic neurodegeneration through ferroptosis. Toxicology. 2019;417:64–73.
   PubMed Web of Science ®Google Scholar
• Hou LY, Sun FQ, Sun W, Zhang L, Wang QS. Lesion of the Locus Coeruleus Damages Learning and Memory Performance in Paraquat and Maneb-induced Mouse Parkinson’s Disease Model. Neuroscience. 2019;419:129–140.
   PubMed Web of Science ®Google Scholar
• Talpade DJ, Greene JG, Higgins DS, Greenamyre JT. In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone. J Neurochem. 2000;75(6):2611–2621.
   PubMed Web of Science ®Google Scholar
• Berry TM, Moustafa AA. A novel treatment strategy to prevent Parkinson’s disease: focus on iron regulatory protein 1 (IRP1). Int J Neurosci. 2023;133(1):67–76.
   PubMed Web of Science ®Google Scholar
• Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 2000;3(12):1301–1306.
   PubMed Web of Science ®Google Scholar
• Ferrante RJ, Schulz JB, Kowall NW, Beal MF. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res. 1997;753(1):157–162.
   PubMed Web of Science ®Google Scholar
• Kabiraj P, Valenzuela CA, Marin JE, et al. The neuroprotective role of ferrostatin-1 under rotenone-induced oxidative stress in dopaminergic neuroblastoma cells. Protein J. 2015;34(5):349–358.
   PubMed Web of Science ®Google Scholar
• Hu CB, Jiang H, Yang Y, et al. DL-3-n-butylphthalide alleviates motor disturbance by suppressing ferroptosis in a rat model of Parkinson’s disease. Neural Regen Res. 2023;18(1):194–199.
   PubMed Web of Science ®Google Scholar
• Avci B, Günaydın C, Külbay M, Kuruca N, Güvenç T, Bilge SS. Neuroprotective effects of sinapic acid involve the iron regulatory role on the rotenone-induced Parkinson’s disease model. Braz J Pharm Sci. 2022;58:e20942.
   Web of Science ®Google Scholar
• Avci B, Günaydın C, Güvenç T, Yavuz CK, Kuruca N, Bilge SS. Idebenone Ameliorates Rotenone-Induced Parkinson’s Disease in Rats Through Decreasing Lipid Peroxidation. Neurochem Res. 2021;46(3):513–522.
   PubMed Web of Science ®Google Scholar
• Mursaleen L, Noble B, Chan SHY, Somavarapu S, Zariwala MG. N-Acetylcysteine Nanocarriers Protect against Oxidative Stress in a Cellular Model of Parkinson’s Disease. Antioxidants (Basel). 2020;9(7):600.
   PubMedGoogle Scholar
• Li H, Shen Y, Xiao H, Sun W. Resveratrol attenuates rotenone-induced inflammation and oxidative stress via STAT1 and Nrf2/Keap1/SLC7A11 pathway in a microglia cell line. Pathol Res Pract. 2021;225:153576.
   PubMed Web of Science ®Google Scholar
• Muñoz-Manchado AB, Villadiego J, Romo-Madero S, et al. Chronic and progressive Parkinson’s disease MPTP model in adult and aged mice. J Neurochem. 2016;136(2):373–387.
   PubMed Web of Science ®Google Scholar
• Zhang QS, Heng Y, Mou Z, Huang JY, Yuan YH, Chen NH. Reassessment of subacute MPTP-treated mice as animal model of Parkinson’s disease. Acta Pharmacol Sin. 2017;38(10):1317–1328.
   PubMed Web of Science ®Google Scholar
• Shi L, Huang C, Luo Q, et al. Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson’s disease through AKT/mTOR pathway. Aging (Albany NY). 2020;12(10):9515–9533.
   PubMedGoogle Scholar
• Bai L, Yan F, Deng R, Gu R, Zhang X, Bai J. Thioredoxin-1 Rescues MPP+/MPTP-Induced Ferroptosis by Increasing Glutathione Peroxidase 4. Mol Neurobiol. 2021;58(7):3187–3197.
   PubMed Web of Science ®Google Scholar
• Lin ZH, Liu Y, Xue NJ, et al. Quercetin Protects against MPP+/MPTP-Induced Dopaminergic Neuron Death in Parkinson’s Disease by Inhibiting Ferroptosis. Oxid Med Cell Longev. 2022;2022:7769355.
   PubMed Web of Science ®Google Scholar
• Ungerstedt U, Ljungberg T, Steg G. Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons. Mol Neurobiol. 1974;421–426.
   Google Scholar
• Bastías-Candia S, Zolezzi JM, Inestrosa NC. Revisiting the Paraquat-Induced Sporadic Parkinson’s Disease-Like Model. Mol Neurobiol. 2019;56(2):1044–1055.
   PubMed Web of Science ®Google Scholar
• Cheng H, Chen Y, Yang HF, Tang X, Zhu WY. Protective Effects of Maprotiline in 6-Hydroxydopamine (6-OHDA)-Induced Ferroptosis in Neuronal Cells. Biomed Nanotechnol. 2022;18(11):2592–2598.
   Web of Science ®Google Scholar
• Sun Y, He L, Wang W, et al. Activation of Atg7-dependent autophagy by a novel inhibitor of the Keap1-Nrf2 protein-protein interaction from Penthorum chinense Pursh. attenuates 6-hydroxydopamine-induced ferroptosis in zebrafish and dopaminergic neurons. Food Funct. 2022;13(14):7885–7900.
   PubMed Web of Science ®Google Scholar
• Gutbier S, Kyriakou S, Schildknecht S, et al. Design and evaluation of bi-functional iron chelators for protection of dopaminergic neurons from toxicants. Arch Toxicol. 2020;94(9):3105–3123.
   PubMed Web of Science ®Google Scholar
• Wang L, An H, Yu F, et al. The neuroprotective effects of paeoniflorin against MPP+-induced damage to dopaminergic neurons via the Akt/Nrf2/GPX4 pathway. J Chem Neuroanat. 2022;122:102103.
   PubMed Web of Science ®Google Scholar
• Liu L, Yang S, Wang H. α-Lipoic acid alleviates ferroptosis in the MPP+ -induced PC12 cells via activating the PI3K/Akt/Nrf2 pathway. Cell Biol Int. 2021;45(2):422–431.
   PubMed Web of Science ®Google Scholar
• Xi J, Zhang Z, Wang Z, et al. Hinokitiol functions as a ferroptosis inhibitor to confer neuroprotection. Free Radic Biol Med. 2022;190:202–215.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Xie G, Alimujiang A, et al. Protective Effects of Querectin against MPP+-Induced Dopaminergic Neurons Injury via the Nrf2 Signaling Pathway. Front Biosci. 2023;28(3):42.
   Web of Science ®Google Scholar
• Bellavite P. Neuroprotective Potentials of Flavonoids: experimental Studies and Mechanisms of Action. Antioxidants (Basel). 2023;12(2):280.
   PubMedGoogle Scholar
• Song LM, Xiao ZX, Zhang N, et al. Apoferritin improves motor deficits in MPTP-treated mice by regulating brain iron metabolism and ferroptosis. iScience. 2021;24(5):102431.
   PubMed Web of Science ®Google Scholar
• Zilka O, Poon JF, Pratt DA. Radical-Trapping Antioxidant Activity of Copper and Nickel Bis(Thiosemicarbazone) Complexes Underlies Their Potency as Inhibitors of Ferroptotic Cell Death. J Am Chem Soc. 2021;143(45):19043–19057.
   PubMed Web of Science ®Google Scholar
• Tourville A, Viguier S, González-Lizárraga F, et al. Rescue of Dopamine Neurons from Iron-Dependent Ferroptosis by Doxycycline and Demeclocycline and Their Non-Antibiotic Derivatives. Antioxidants (Basel). 2023;12(3):575.
   PubMedGoogle Scholar
• Wang Y, Wu S, Li Q, et al. Epigallocatechin-3-gallate: a phytochemical as a promising drug candidate for the treatment of Parkinson’s disease. Front Pharmacol. 2022;13:977521.
   PubMed Web of Science ®Google Scholar
• Chen D, Kanthasamy AG, Reddy MB. EGCG Protects against 6-OHDA-Induced Neurotoxicity in a Cell Culture Model. Parkinsons Dis. 2015;2015:843906.
   PubMed Web of Science ®Google Scholar
• Hirata Y, Yamada C, Ito Y, et al. Novel oxindole derivatives prevent oxidative stress-induced cell death in mouse hippocampal HT22 cells. Neuropharmacology. 2018;135:242–252.
   PubMed Web of Science ®Google Scholar
• Nebie O, Devos D, Vingtdeux V, et al. The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates. J Biomed Sci. 2019;26(1):89.
   PubMed Web of Science ®Google Scholar
• Gouel F, Do Van B, Chou ML, et al. The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways. J Tissue Eng Regen Med. 2017;11(11):3236–3240.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhang J, Zhang Y, et al. Proteomic Analysis of Protective Effects of Dl-3-n-Butylphthalide against mpp + -Induced Toxicity via downregulating P53 pathway in N2A Cells. Proteome Sci. 2023;21(1):1.
   PubMed Web of Science ®Google Scholar
• Grolez G, Moreau C, Sablonnière B, et al. Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease. BMC Neurol. 2015;15:74.
   PubMed Web of Science ®Google Scholar
• Cabantchik ZI, Munnich A, Youdim MB, Devos D. Regional siderosis: a new challenge for iron chelation therapy. Front Pharmacol. 2013;4:167. doi:10.3389/fphar.2013.00167
   PubMed Web of Science ®Google Scholar
• Devos D, Labreuche J, Rascol O, et al. Trial of Deferiprone in Parkinson’s Disease. N Engl J Med. 2022;387(22):2045–2055. doi:10.1056/NEJMoa2209254
   PubMed Web of Science ®Google Scholar
• Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541–1550.
   PubMed Web of Science ®Google Scholar
• Seet RC, Lim EC, Tan JJ, et al. Does high-dose coenzyme Q10 improve oxidative damage and clinical outcomes in Parkinson’s disease?. Antioxid Redox Signal. 2014;21(2):211–217.
   PubMed Web of Science ®Google Scholar
• Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol. 2007;64(7):938–944.
   PubMedGoogle Scholar
• Enns GM, Kinsman SL, Perlman SL, et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab. 2012;105(1):91–102.
   PubMed Web of Science ®Google Scholar
• Mischley LK, Lau RC, Shankland EG, Wilbur TK, Padowski JM. Phase IIb Study of Intranasal Glutathione in Parkinson’s Disease. J Parkinsons Dis. 2017;7(2):289–299.
   PubMedGoogle Scholar
• Beal MF, Oakes D; Parkinson Study Group QEI. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543–552.
   PubMed Web of Science ®Google Scholar
• Investigators NN-P. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68(1):20–28.
   PubMed Web of Science ®Google Scholar